Pfizer vaccine: an immunologist explains

Naked Scientists, In Short Special Editions Podcast

Pfizer and BioNTech have concluded the Phase 3 trial of their coronavirus vaccine. The results appear to show an efficacy rate of 95%, and the developers hope to win FDA approval as soon as possible. This vaccine - a promising hope for many - works via a new methiod that's never been tried before in humans. Chris Smith asked Cambridge University immunologist Clare Bryant for her reaction... Like this podcast? Please help us by supporting the Naked Scientists

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada